Cargando…

POS-939 EFFICACY OF BNT162b2 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS IN NORTH OF PORTUGAL

Detalles Bibliográficos
Autores principales:	FRANCISCO, J., Beirão, B., Freitas, M., Sousa, C., Pereira, P., Castro, R., Morgado, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854880/ http://dx.doi.org/10.1016/j.ekir.2022.01.979

Ejemplares similares

POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS
por: BEIRÃO, B., et al.
Publicado: (2022)

POS-940 ANTIBODY RESPONSE TO PFIZER BNT162b2 VACCINE IN HEMODIALYSIS PATIENTS: THE PREVIOUS SARS-CoV-2 INFECTION INFLUENCE
por: FREITAS, M., et al.
Publicado: (2022)

POS-923 RESPONSE TO AND OUTCOMES OF THE Pfizer BNT162B2 VACCINE IN HEMODIALYSIS PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY
por: AlMuhaiteeb, A., et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
por: Yau, Kevin, et al.
Publicado: (2021)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS
por: Yau, K., et al.
Publicado: (2022)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

POS-793 UNDERGOING HEMODIALYSIS DURING COVID-19 LOCKDOWN: EXPLORING PATIENTS' AND FAMILY CAREGIVERS' EXPERIENCES
por: FIGUEIREDO, D., et al.
Publicado: (2021)

Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study
por: Mirioglu, Safak, et al.
Publicado: (2023)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up
por: Weigert, André, et al.
Publicado: (2021)

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

POS-896 QUALITY OF LIFE OF FAMILY CAREGIVERS OF PATIENTS UNDERGOING IN-CENTER HEMODIALYSIS DURING THE COVID-19 PANDEMIC: PRELIMINARY RESULTS
por: FIGUEIREDO, D., et al.
Publicado: (2022)

Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients—A prospective observational study
por: Al‐Muhaiteeb, Abdullah, et al.
Publicado: (2022)

Immune Senescence Markers Predict the Cellular Immune Response to BNT162b2 Vaccination in Hemodialysis Patients
por: Van Praet, Jens T, et al.
Publicado: (2022)

Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer
por: Ikeda, Atsushi, et al.
Publicado: (2015)

BNT-162b1/clobetasol: Pernio and lack of efficacy: case report
Publicado: (2022)

Bioactivity Studies of Hesperidin and XAV939
por: Fazary, Ahmed E., et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
por: Goupil, Rémi, et al.
Publicado: (2021)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

POS-553 PRESENCE AND SEVERITY OF COVID-19 PANDEMIC-ASSOCIATED DEPRESSION IN PATIENTS UNDERGOING HEMODIALYSIS AT THE TARIJA DEPARTMENTAL NEPHROLOGY AND HEMODIALYSIS CENTER – BOLIVIA
por: ZAMORA, N., et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients
por: Ben-Aharon, I., et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

POS-922 Psychological Impact of Covid 19 in Hemodialysis Patients
por: ALAFIFI, R., et al.
Publicado: (2022)

Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
por: Kitamura, Mineaki, et al.
Publicado: (2022)

SUN-939 Case Report: Malignant Pheochromocytoma
por: Lima, Jose Viana, et al.
Publicado: (2020)

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2021)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
por: Clavero, Rene, et al.
Publicado: (2022)

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s6d4ejjkvcba7gm51qenn20m7i